查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2020210

肌萎縮側索硬化症 (ALS) 治療市場：規模、佔有率、成長和全球產業分析（按類型和應用）、區域洞察以及 2026-2034 年預測

Amyotrophic Lateral Sclerosis Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 100 Pages | 商品交期: 請詢問到貨日

價格

肌萎縮側索硬化症 (ALS) 治療市場的成長要素

全球肌萎縮側索硬化症 (ALS) 治療市場預計在 2025 年達到 8.9 億美元，2026 年成長至 10.3 億美元，最終在 2034 年達到 21.9 億美元，在 2026 年至 2034 年的預測期內，複合年成長率將達到 9.93%。北美在 2025 年將以 54.37% 的市佔率領先，這主要得益於已通過核准藥物的商業化以及該地區對 ALS 的認知不斷提高。

肌萎縮側索硬化症（ALS），又稱漸路格裡克氏病，是一種進行性神經退化性疾病，會導致肌肉無力並損害身體機能。目前尚無根治性，但托福生、Edaravone和Riluzole等治療方法可以幫助控制症狀並延緩疾病進展。 ALS盛行率的上升以及ALS協會、I AM ALS、ACELA和荷蘭ALS協會等組織開展的宣傳活動，正在推動這些藥物的市場需求。

新冠疫情期間，由於就診量減少、供應鏈中斷，ALS治療市場出現萎縮。然而，從2021年到2022年，隨著疾病負擔加重，更多患者尋求有效治療，市場開始復甦。

市場趨勢

市場關鍵趨勢之一是開發用於治療肌萎縮側索硬化症（ALS）的新藥。各公司正積極進行臨床試驗，力求將創新治療方法推向市場。例如，AL-S Pharma於2021年啟動了AP-101的II期臨床試驗，預計將於2025年1月完成。同樣，Clene Nanomedicine也啟動了CNMAu8的II期臨床試驗，預計將於2024年12月完成。對新治療方法的關注預計將顯著推動市場成長。

成長要素

全球肌萎縮側索硬化症（ALS）治療市場的需求成長主要受ALS患者日益沉重的負擔以及各國政府支持研發的舉措所驅動。像Radica（Edaravone）這樣獲得美國FDA核准的藥物需求量很大，因為它們可以延緩疾病的進展。 ALS的盛行率在全球呈上升趨勢。例如，在義大利撒丁島，ALS的盛行率從2015年的每10萬人15.26例上升到2019年的每10萬人18.31例。世界各國政府都在加大對ALS研究的投入，以拓展治療方法選擇；例如，加拿大透過加拿大衛生研究院（CIHR）在2023年投入了4000萬美元。

抑制因子

肌萎縮側索硬化症（ALS）藥物的高昂費用和副作用限制了市場成長。例如，Radicava 等藥物每年費用高達 17.1 萬美元左右，並可能導致頭暈、虛弱和呼吸困難。由於患者傾向於選擇營養支持、語言治療、物理治療和手術等替代療法，高昂的費用和副作用阻礙了 ALS 藥物的普及。

市場區隔

依藥物類型：

  • 由於依達拉奉獲得了全球核准，並且有口服和注射兩種給藥途徑，預計到 2026 年，Edaravone奉將引領市場，佔 57.88% 的市場佔有率。
  • 其他藥物，包括正在研發中的藥物，如 CNMAu8、MRG-001 和 AP-101，也顯示出很高的成長潛力。

依管理途徑：

  • 到 2026 年，口服藥物預計將佔市場主導地位，市場佔有率達到 50.24%，這主要得益於 Relyvrio、Radicava 和 Rilutek 等口服製劑的推動。
  • 預計注射劑藥物領域將以最高的複合年成長率成長，這得益於 QALSODY 的核准。

按分銷管道：

  • 到 2026 年，醫院藥局將佔市場領先地位，市場佔有率達到 54.29%，這得益於專業的員工隊伍和病患的偏好。
  • 受孤兒藥線上分銷的推動，零售藥局和網路藥局的成長速度最快。

區域趨勢

預計北美將在2025年以4.8億美元的市場規模佔主導地位，並在2026年達到5.5億美元，這主要得益於強效藥物的商業化和核准。光是美國市場預計在2026年就將達到5.04億美元。

2025 年歐洲市場將達到 2.4 億美元，預計到 2026 年將成長至 2.7 億美元，這得益於 QALSODY 和 Radicava 的商業化以及管道核准。

預計亞太地區市場規模將在2025年達到9,000萬美元，2026年達到1.2億美元。 PTC Therapeutics和Clene Nanomedicine公司不斷提高的市場認知度和臨床試驗預計將推動該地區實現最高的複合年成長率。預計日本市場規模將在2025年達到3,160萬美元，中國市場規模將在2026年達到2,800萬美元，印度市場規模將在2026年達到900萬美元。

世界其他地區由於人們對 ALS 的認知提高和患病率上升，預計將出現顯著成長。

主要企業

主要市場參與者包括百健（Biogen）、田邊三菱製藥（Tanabe Mitsubishi Pharma）、賽諾菲（Sanofi）、EDW製藥（EDW Pharma）、Aculicit Therapeutics、大塚製藥（Otsuka Pharmaceutical）、諾華（Novartis）、Zydus Life Sciences、Crane Nanomedicine、Crane Nano。這些公司正專注於藥物商業化、臨床試驗併購，以加強產品系列。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章：主要考慮因素

  • 肌萎縮側索硬化症的流行病學—按主要國家和地區分類，2025 年
  • 管道分析：按主要企業分類
  • 主要產業趨勢（合併、收購、合作等）
  • 新冠疫情對市場的影響

第5章：全球市場分析、洞察與預測（2021-2034年）

  • 市場分析、洞察與預測：按藥物類型分類
    • 託費爾森
    • Edaravone
    • Riluzole
    • 其他
  • 市場分析、洞察與預測：按給藥途徑
    • 口服
    • 腸外
  • 市場分析、洞察與預測：按分銷管道分類
    • 醫院藥房
    • 實體店和網路藥局
  • 市場分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 世界其他地區

第6章：北美市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 其他歐洲國家

第8章：亞太市場分析、洞察與預測（2021-2034年）

  • 國家
    • 日本
    • 中國
    • 澳洲
    • 印度
    • 其他亞太國家

第9章：2021-2034年世界其他地區市場分析、洞察與預測

第10章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • Biogen
    • Mitsubishi Tanabe Pharma
    • Sanofi
    • EDW Pharma, Inc.
    • Aquestive Therapeutics
    • Otsuka Pharmaceutical, Inc.
    • Novartis Pharmaceuticals
    • Zydus Lifesciences Limited
    • Clene Nanomedicine
    • Annexon, Inc.
Product Code: FBI110139

Growth Factors of amyotrophic lateral sclerosis (ALS) therapeutics Market

The global amyotrophic lateral sclerosis (ALS) therapeutics market was valued at USD 0.89 billion in 2025 and is projected to grow to USD 1.03 billion in 2026, ultimately reaching USD 2.19 billion by 2034, registering a CAGR of 9.93% during the forecast period of 2026-2034. North America led the market in 2025 with a share of 54.37%, attributed to the commercialization of approved drugs and heightened awareness of ALS in the region.

ALS, also known as Lou Gehrig's disease, is a progressive neurodegenerative disorder that weakens muscles and impairs physical function. Although no cure exists, treatments such as tofersen, edaravone, and riluzole help manage symptoms and slow disease progression. The rising prevalence of ALS and increasing awareness driven by organizations like ALS Association, I AM ALS, ACELA, ALS Netherlands, and others have boosted market demand for therapeutics.

During the COVID-19 pandemic, the ALS therapeutics market experienced a decline due to reduced hospital visits for diagnosis and treatment, along with supply chain disruptions. However, market recovery occurred in 2021-2022 as the disease burden increased and more patients sought effective care.

Market Trends

One of the key trends in the market is the development of novel drugs for ALS treatment. Companies are actively engaging in clinical trials to bring innovative therapies to the market. For example, AL-S Pharma initiated phase 2 trials for AP-101 in 2021, expected to complete in January 2025, and Clene Nanomedicine started phase 2 trials for CNMAu8, completing in December 2024. The emphasis on new therapeutics is expected to significantly drive market growth.

Growth Factors

The global ALS therapeutics market is fueled by the growing burden of ALS and government initiatives supporting research and development. Drugs like Radicava (edaravone), approved by the U.S. FDA, slow disease progression, increasing demand. The prevalence of ALS has been rising worldwide; for instance, in Sardinia, Italy, ALS prevalence increased from 15.26 per 100,000 in 2015 to 18.31 per 100,000 in 2019. Governments are investing in research, such as Canada's USD 40 million funding via CIHR in 2023, to advance therapeutic options.

Restraining Factors

High costs and side effects associated with ALS drugs limit market growth. Treatments like Radicava can cost approximately USD 171,000 per year and may cause dizziness, weakness, and breathing issues. The high cost and adverse effects often push patients toward alternative therapies, including nutritional support, speech therapy, physical therapy, and surgery, restraining the adoption of ALS therapeutics.

Market Segmentation

By Drug Type:

  • Edaravone is projected to dominate with 57.88% share in 2026, driven by global approvals and oral/parenteral availability.
  • Others, including pipeline drugs like CNMAu8, MRG-001, and AP-101, also show strong growth potential.

By Route of Administration:

  • Oral drugs dominated in 2026 with 50.24% share, driven by Relyvrio and other oral formulations like Radicava and Rilutek.
  • The parenteral segment is expected to grow at the fastest CAGR, aided by QALSODY's approval.

By Distribution Channel:

  • Hospital pharmacies led with 54.29% share in 2026, supported by trained staff and patient preference.
  • Retail and online pharmacies are growing fastest, facilitated by orphan drug distribution online.

Regional Insights

North America dominated in 2025 with USD 0.48 billion, projected to reach USD 0.55 billion in 2026 due to strong drug commercialization and approvals. The U.S. market alone is forecast to reach USD 0.504 billion in 2026.

Europe contributed USD 0.24 billion in 2025, expected to grow to USD 0.27 billion in 2026, supported by QALSODY and Radicava commercialization and pipeline approvals.

Asia Pacific had USD 0.09 billion in 2025, projected to reach USD 0.12 billion in 2026, experiencing the fastest CAGR due to rising awareness and clinical trials by PTC Therapeutics and Clene Nanomedicine. Japan is expected at USD 31.6 million in 2025, China at USD 0.028 billion in 2026, and India at USD 0.009 billion in 2026.

The rest of the world is anticipated to grow substantially due to increased awareness and ALS prevalence.

Key Players

Prominent market players include Biogen, Mitsubishi Tanabe Pharma, Sanofi, EDW Pharma, Aquestive Therapeutics, Otsuka Pharmaceutical, Novartis, Zydus Lifesciences, Clene Nanomedicine, and Annexon. These companies focus on drug commercialization, clinical trials, and mergers & acquisitions to enhance their product portfolios.

Recent Developments:

  • May 2024: Biogen received European approval for QALSODY.
  • May 2022: Mitsubishi Tanabe Pharma gained U.S. FDA approval for Radicava.
  • May 2022: Sanofi initiated Phase 2 HIMALAYA Study for SAR443820.
  • March 2022: Aquestive Therapeutics licensed Riluzole oral film in China.

Conclusion

The global amyotrophic lateral sclerosis therapeutics market is projected to exhibit strong growth from USD 0.89 billion in 2025 to USD 2.19 billion by 2034 at a CAGR of 9.93%, driven by rising ALS prevalence, novel drug development, and supportive government initiatives. However, high treatment costs and side effects may restrain adoption, while oral drug formulations and hospital pharmacy distribution dominate market segments. North America remains the largest market, with Asia Pacific demonstrating the fastest growth potential.

Segmentation By Drug Type

  • Tofersen
  • Edaravone
  • Riluzole
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospital Pharmacy
  • Retail & Online Pharmacy

By Region

  • North America (by Drug Type, by Route of Administration, by Distribution Channel, and by Country)
    • U.S.
    • Canada
  • Europe (by Drug Type, by Route of Administration, by Distribution Channel, and by Country/Sub-region)
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific (by Drug Type, by Route of Administration, by Distribution Channel, and by Country/Sub-region)
    • Japan
    • China
    • Australia
    • India
    • Rest of Asia Pacific
  • Rest of the World (by Drug Type, by Route of Administration, and by Distribution Channel)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Epidemiology of Amyotrophic Lateral Sclerosis - by Key Countries/Regions, 2025
  • 4.2. Pipeline Analysis - by Key Companies
  • 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.4. Impact of COVID-19 on the Market

5. Global Amyotrophic Lateral Sclerosis Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Type
    • 5.1.1. Tofersen
    • 5.1.2. Edaravone
    • 5.1.3. Riluzole
    • 5.1.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Parenteral
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital Pharmacy
    • 5.3.2. Retail & Online Pharmacy
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Rest of the World

6. North America Amyotrophic Lateral Sclerosis Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Type
    • 6.1.1. Tofersen
    • 6.1.2. Edaravone
    • 6.1.3. Riluzole
    • 6.1.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Parenteral
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital Pharmacy
    • 6.3.2. Retail & Online Pharmacy
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Amyotrophic Lateral Sclerosis Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Type
    • 7.1.1. Tofersen
    • 7.1.2. Edaravone
    • 7.1.3. Riluzole
    • 7.1.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Parenteral
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital Pharmacy
    • 7.3.2. Retail & Online Pharmacy
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Rest of Europe

8. Asia Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Type
    • 8.1.1. Tofersen
    • 8.1.2. Edaravone
    • 8.1.3. Riluzole
    • 8.1.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Parenteral
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital Pharmacy
    • 8.3.2. Retail & Online Pharmacy
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. Australia
    • 8.4.4. India
    • 8.4.5. Rest of Asia Pacific

9. Rest of the World Amyotrophic Lateral Sclerosis Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Type
    • 9.1.1. Tofersen
    • 9.1.2. Edaravone
    • 9.1.3. Riluzole
    • 9.1.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Parenteral
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital Pharmacy
    • 9.3.2. Retail & Online Pharmacy

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2025)
  • 10.2. Company Profiles
    • 10.2.1. Biogen
      • 10.2.1.1. Overview
      • 10.2.1.2. Products & services
      • 10.2.1.3. SWOT Analysis
      • 10.2.1.4. Recent Developments
      • 10.2.1.5. Strategies
      • 10.2.1.6. Financials (Based on Availability)
    • 10.2.2. Mitsubishi Tanabe Pharma
      • 10.2.2.1. Overview
      • 10.2.2.2. Products & services
      • 10.2.2.3. SWOT Analysis
      • 10.2.2.4. Recent Developments
      • 10.2.2.5. Strategies
      • 10.2.2.6. Financials (Based on Availability)
    • 10.2.3. Sanofi
      • 10.2.3.1. Overview
      • 10.2.3.2. Products & services
      • 10.2.3.3. SWOT Analysis
      • 10.2.3.4. Recent Developments
      • 10.2.3.5. Strategies
      • 10.2.3.6. Financials (Based on Availability)
    • 10.2.4. EDW Pharma, Inc.
      • 10.2.4.1. Overview
      • 10.2.4.2. Products & services
      • 10.2.4.3. SWOT Analysis
      • 10.2.4.4. Recent Developments
      • 10.2.4.5. Strategies
      • 10.2.4.6. Financials (Based on Availability)
    • 10.2.5. Aquestive Therapeutics
      • 10.2.5.1. Overview
      • 10.2.5.2. Products & services
      • 10.2.5.3. SWOT Analysis
      • 10.2.5.4. Recent Developments
      • 10.2.5.5. Strategies
      • 10.2.5.6. Financials (Based on Availability)
    • 10.2.6. Otsuka Pharmaceutical, Inc.
      • 10.2.6.1. Overview
      • 10.2.6.2. Products & services
      • 10.2.6.3. SWOT Analysis
      • 10.2.6.4. Recent Developments
      • 10.2.6.5. Strategies
      • 10.2.6.6. Financials (Based on Availability)
    • 10.2.7. Novartis Pharmaceuticals
      • 10.2.7.1. Overview
      • 10.2.7.2. Products & services
      • 10.2.7.3. SWOT Analysis
      • 10.2.7.4. Recent Developments
      • 10.2.7.5. Strategies
      • 10.2.7.6. Financials (Based on Availability)
    • 10.2.8. Zydus Lifesciences Limited
      • 10.2.8.1. Overview
      • 10.2.8.2. Products & services
      • 10.2.8.3. SWOT Analysis
      • 10.2.8.4. Recent Developments
      • 10.2.8.5. Strategies
      • 10.2.8.6. Financials (Based on Availability)
    • 10.2.9. Clene Nanomedicine
      • 10.2.9.1. Overview
      • 10.2.9.2. Products & services
      • 10.2.9.3. SWOT Analysis
      • 10.2.9.4. Recent Developments
      • 10.2.9.5. Strategies
      • 10.2.9.6. Financials (Based on Availability)
    • 10.2.10. Annexon, Inc.
      • 10.2.10.1. Overview
      • 10.2.10.2. Products & services
      • 10.2.10.3. SWOT Analysis
      • 10.2.10.4. Recent Developments
      • 10.2.10.5. Strategies
      • 10.2.10.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 2: Global Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 3: Global Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 5: North America Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 6: North America Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 7: North America Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 9: Europe Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 10: Europe Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 11: Europe Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 14: Asia Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 15: Asia Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Rest of the World Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 18: Rest of the World Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 19: Rest of the World Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034a

List of Figures

  • Figure 1: Global Amyotrophic Lateral Sclerosis Therapeutics Market Revenue Breakdown (USD billion, %) by Region, 2021 & 2034
  • Figure 2: Global Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Drug Type, 2021 & 2034
  • Figure 3: Global Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Route of Administration, 2021 & 2034
  • Figure 4: Global Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Distribution Channel, 2021 & 2034
  • Figure 5: Global Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), by Region, 2021 & 2034
  • Figure 6: North America Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), by Drug Type, 2021 & 2034
  • Figure 7: North America Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Drug Type, 2025
  • Figure 8: North America Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), by Route of Administration, 2021 & 2034
  • Figure 9: North America Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 10: North America Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), by Distribution Channel, 2021 & 2034
  • Figure 11: North America Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 12: North America Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), By Country, 2021 & 2034
  • Figure 13: North America Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), By Country, 2025
  • Figure 14: Europe Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), by Drug Type, 2021 & 2034
  • Figure 15: Europe Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Drug Type, 2025
  • Figure 16: Europe Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), by Route of Administration, 2021 & 2034
  • Figure 17: Europe Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 18: Europe Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), by Distribution Channel, 2021 & 2034
  • Figure 19: Europe Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 20: Europe Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), By Country/ Sub-region, 2021 & 2034
  • Figure 21: Europe Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), by Drug Type, 2021 & 2034
  • Figure 23: Asia Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Drug Type, 2025
  • Figure 24: Asia Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), by Route of Administration, 2021 & 2034
  • Figure 25: Asia Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 26: Asia Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), by Distribution Channel, 2021 & 2034
  • Figure 27: Asia Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 28: Asia Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), By Country/ Sub-region, 2021 & 2034
  • Figure 29: Asia Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Rest of the World Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), by Drug Type, 2021 & 2034
  • Figure 31: Latin America Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Drug Type, 2025
  • Figure 32: Rest of the World Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), by Route of Administration, 2021 & 2034
  • Figure 33: Rest of the World Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 34: Rest of the World Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), by Distribution Channel, 2021 & 2034
  • Figure 35: Rest of the World Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 36: Global Amyotrophic Lateral Sclerosis Therapeutics Market Share (%), By Company, 2025